Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Earlier-Stage Approvals For Tecentriq, Keytruda, Verzenio Underscore Broader Oncology Trends

Oct 15 2021

• By Bridget Silverman

Keeping Track Feature image

Related Content

Roche’s Tecentriq Glows In Pivotal Trial For Early Lung Cancer

Mar 22 2021

Enhertu Poised To Rewrite The Standard Of Care After ESMO

Sep 20 2021

Lilly’s Early Bird Verzenio Goes After Up To S4bn Worm With Early Breast Cancer Nod

Oct 13 2021

Keytruda Cements Cervical Cancer Leadership With First-Line Nod

Oct 14 2021

Gilead/Kite’s Tecartus Moves Into Leukemia With Second US Indication

Oct 04 2021

Keeping Track: US FDA Acts On 5 Novel Drugs: Approval For Fotivda, Pepaxto, Azstarys; CRLs For Defencath and Oral Paclitaxel

Mar 15 2021

Related Companies

Genentech, Inc.

Merck & Co., Inc.

Agilent Technologies, Inc.

Eli Lilly and Company

Daiichi Sankyo Co., Ltd.

AstraZeneca PLC

Athenex, Inc.

Hanmi Pharmaceutical Co., Ltd.

Gilead Sciences, Inc.

Additional Topics

United States Approvals Drug Review Drug Approval Standards Complete Response Letters Regulation US FDA Performance Tracker Cancer BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window